Stroke Management Market – Global Industry Analysis and Forecast (2023-2029)


Stroke Management Market is expected to reach US$ 42.99 Bn. at a CAGR of 6% during the forecast period 2029.

Stroke occurs due to interruptions in the blood supply to brain, either due to the rupture or blockage of blood vessels, leading to the death of brain cells.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. Stroke Management MarkeTo know about the Research Methodology  :- Request Free Sample Report

Stroke Management Market Dynamics

High blood pressure, high cholesterol levels and obesity, heart diseases, diabetes, sickle cell disease, smoking, alcoholic and excessive drug consumption are some of the major factors that can increase the chances of strokes. Blood pressure is one of the major causes where number of strokes that results in several death across the world. Also, heart diseases such as coronary artery disease, arrhythmia, atrial fibrillation, and enlarged heart chambers increase the risk of strokes.

Factors such as technological advancement, growing aging population, and people suffering from diabetes are favoring the stroke market. On the other hand, increasing health expenditure, hypertension and also increasing tobacco users are also fuelling the market. However factors such as unfavorable reimbursement scenario and high cost of treatments are hampering the market growth. Unhealthy lifestyle is another significant factor driving demand for stroke diagnostic products.

Stroke Management Market Segment Analysis

Imaging studies are used in ischemic diagnosis for the detection of hemorrhage in the acute stroke patient, in order to assess the degree of brain injury, and to identify the vascular lesion responsible for the ischemic deficit. Some advanced CT and MRI technologies are able to distinguish between brain tissue that is irreversibly infracted and that which is potentially salvageable, thereby allowing better selection of patients likely to benefit from therapy. In 2022, the leading diagnostic segment was computed tomography. The highest share of CT techniques is attributable to widespread access and speed of acquisition. In the hyper acute phase, a noncontrast CT (NCCT) scan is usually ordered to exclude or confirm hemorrhage; it is highly sensitive for this indication.

Ischemic stroke segment is expected to witness around xx% CAGR during the forecast timeframe owing to rising incidence of ischemic stroke in developed as well as developing countries.

The market dominance of the North America is attributed to high percentage of patients suffering from strokes, in admiration with the technical advancement in the treatment procedure acute ischemic stroke in the region. It is then followed by Europe; the large population of baby boomers in Europe is one of the factors for a high market share in acute ischemic stroke diagnosis and treatment market. Country wise, the U.S., Canada are two of the major markets in North America. Germany, Italy, the U.K, and France are some of the dominant market in Europe, Japan, China and India are the major market of Asia Pacific region.

The objective of the report is to present comprehensive analysis of Global Stroke Management Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Stroke Management Market dynamics, structure by analyzing the market segments, and project the Global Stroke Management Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Stroke Management Market make the report investor’s guide.

Stroke Management Market Scope: Inquire before buying






Global Stroke Management Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 28.58 Bn.




Forecast Period 2023 to 2029 CAGR:
6%
Market Size in 2029:
US $ 42.99 Bn.




 Segments Covered:
by Type
Diagnostics
Computed Tomography Scan (CT Scan),
Echocardiography Magnetic Resonance Imaging (MRI)
Carotid Ultrasound,
Cerebral Angiography,
Electrocardiography
Therapeutics
Tissue Plasminogen Activator,
Anticoagulant,
Antiplatelet,
Antihypertensive




by Application
Ischemic Stroke
Haemorrhagic Stroke






Stroke Management Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Stroke Management Market Key Players

1. Abbott Laboratories
2. Covidien PLC
3. GE Healthcare
4. Hitachi, Ltd
5. Johnson and Johnson
6. Penumbra, Inc.
7. Philips Healthcare
8. Siemens Healthcare
9. Stryker Corporation (Concentric Medical, Inc.)
10.B. Braun Melsungen Ag
11.Boston Scientific Corporation
12.Cardinal Health, Inc.
13.Glaxosmithkline Plc
14.Medtronic Plc.
15.Merck & Co., Inc.
16.Bristol-Myers Squibb Company
17.Koninklijke Philips N.V.
18.ZOLL Medical Corporation
19.Mizuho Medical Co., Ltd.
20.Integer Holdings Corporation
21.GENERAL ELECTRIC COMPANY
22.Kaneka Pharma America LLC
23.Silk Road Medical
24.Teleflex Incorporated

Frequently Asked Questions:

1. Which region has the largest share in Stroke Management Market?
Ans: North America region holds the highest share in 2022.

2. What is the growth rate of Stroke Management Market?
Ans: The Stroke Management Market is growing at a CAGR of 6% during forecasting period 2023-2029.

3. What is scope of the Stroke Management market report?
Ans: Stroke Management Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Stroke Management market?
Ans: The important key players in the Stroke Management Market are – Abbott Laboratories, Covidien PLC, GE Healthcare, Hitachi, Ltd, Johnson and Johnson, Penumbra, Inc., Philips Healthcare, Siemens Healthcare, Stryker Corporation, B. Braun Melsungen Ag, Cardinal Health, Inc., Glaxosmithkline Plc, Medtronic Plc., Merck & Co., Inc., Bristol-Myers Squibb Company, Koninklijke Philips N.V., ZOLL Medical Corporation, Mizuho Medical Co., Ltd., Integer Holdings Corporation, GENERAL ELECTRIC COMPANY, Kaneka Pharma America LLC, Silk Road Medical, and Teleflex Incorporated.

5. What is the study period of this market?
Ans: The Stroke Management Market is studied from 2022 to 2029. 




Stroke Management market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Stroke management Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Stroke management Market Analysis and Forecast
6.1. Global Stroke management Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Stroke management Market Analysis and Forecast, By Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Stroke management Market Value Share Analysis, By Type
7.4. Global Stroke management Market Size (US$ Bn) Forecast, By Type
7.5. Global Stroke management Market Analysis, By Type
7.6. Global Stroke management Market Attractiveness Analysis, By Type

8. Global Stroke management Market Analysis and Forecast, By Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Stroke management Market Value Share Analysis, By Application
8.4. Global Stroke management Market Size (US$ Bn) Forecast, By Application
8.5. Global Stroke management Market Analysis, By Application
8.6. Global Stroke management Market Attractiveness Analysis, By Application

9. Global Stroke management Market Analysis, by Region
9.1. Global Stroke management Market Value Share Analysis, by Region
9.2. Global Stroke management Market Size (US$ Bn) Forecast, by Region
9.3. Global Stroke management Market Attractiveness Analysis, by Region

10. North America Stroke management Market Analysis
10.1. Key Findings
10.2. North America Stroke management Market Overview
10.3. North America Stroke management Market Value Share Analysis, By Type
10.4. North America Stroke management Market Forecast, By Type
10.4.1. Diagnostics
10.4.1.1. Computed Tomography Scan (CT Scan),
10.4.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
10.4.1.3. Carotid Ultrasound,
10.4.1.4. Cerebral Angiography,
10.4.1.5. Electrocardiography
10.4.2. Therapeutics
10.4.2.1. Tissue Plasminogen Activator,
10.4.2.2. Anticoagulant,
10.4.2.3. Antiplatelet,
10.4.2.4. Antihypertensive
10.5. North America Stroke management Market Value Share Analysis, By Application
10.6. North America Stroke management Market Forecast, By Application
10.6.1. Ischemic Stroke
10.6.2. Haemorrhagic Stroke
10.7. North America Stroke management Market Value Share Analysis, by Country
10.8. North America Stroke management Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Stroke management Market Analysis, by Country
10.10. U.S. Stroke management Market Forecast, By Type
10.10.1. Diagnostics
10.10.1.1. Computed Tomography Scan (CT Scan),
10.10.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
10.10.1.3. Carotid Ultrasound,
10.10.1.4. Cerebral Angiography,
10.10.1.5. Electrocardiography
10.10.2. Therapeutics
10.10.2.1. Tissue Plasminogen Activator,
10.10.2.2. Anticoagulant,
10.10.2.3. Antiplatelet,
10.10.2.4. Antihypertensive
10.11. U.S. Stroke management Market Forecast, By Application
10.11.1. Ischemic Stroke
10.11.2. Haemorrhagic Stroke
10.12. Canada Stroke management Market Forecast, By Type
10.12.1. Diagnostics
10.12.1.1. Computed Tomography Scan (CT Scan),
10.12.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
10.12.1.3. Carotid Ultrasound,
10.12.1.4. Cerebral Angiography,
10.12.1.5. Electrocardiography
10.12.2. Therapeutics
10.12.2.1. Tissue Plasminogen Activator,
10.12.2.2. Anticoagulant,
10.12.2.3. Antiplatelet,
10.12.2.4. Antihypertensive
10.13. Canada Stroke management Market Forecast, By Application
10.13.1. Ischemic Stroke
10.13.2. Haemorrhagic Stroke
10.14. North America Stroke management Market Attractiveness Analysis
10.14.1. By Type
10.14.2. By Application
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Stroke management Market Analysis
11.1. Key Findings
11.2. Europe Stroke management Market Overview
11.3. Europe Stroke management Market Value Share Analysis, By Type
11.4. Europe Stroke management Market Forecast, By Type
11.4.1. Diagnostics
11.4.1.1. Computed Tomography Scan (CT Scan),
11.4.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.4.1.3. Carotid Ultrasound,
11.4.1.4. Cerebral Angiography,
11.4.1.5. Electrocardiography
11.4.2. Therapeutics
11.4.2.1. Tissue Plasminogen Activator,
11.4.2.2. Anticoagulant,
11.4.2.3. Antiplatelet,
11.4.2.4. Antihypertensive
11.5. Europe Stroke management Market Value Share Analysis, By Application
11.6. Europe Stroke management Market Forecast, By Application
11.6.1. Ischemic Stroke
11.6.2. Haemorrhagic Stroke
11.7. Europe Stroke management Market Value Share Analysis, by Country
11.8. Europe Stroke management Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Stroke management Market Analysis, by Country
11.10. Germany Stroke management Market Forecast, By Type
11.10.1. Diagnostics
11.10.1.1. Computed Tomography Scan (CT Scan),
11.10.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.10.1.3. Carotid Ultrasound,
11.10.1.4. Cerebral Angiography,
11.10.1.5. Electrocardiography
11.10.2. Therapeutics
11.10.2.1. Tissue Plasminogen Activator,
11.10.2.2. Anticoagulant,
11.10.2.3. Antiplatelet,
11.10.2.4. Antihypertensive
11.11. Germany Stroke management Market Forecast, By Application
11.11.1. Ischemic Stroke
11.11.2. Haemorrhagic Stroke
11.12. U.K. Stroke management Market Forecast, By Type
11.12.1. Diagnostics
11.12.1.1. Computed Tomography Scan (CT Scan),
11.12.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.12.1.3. Carotid Ultrasound,
11.12.1.4. Cerebral Angiography,
11.12.1.5. Electrocardiography
11.12.2. Therapeutics
11.12.2.1. Tissue Plasminogen Activator,
11.12.2.2. Anticoagulant,
11.12.2.3. Antiplatelet,
11.12.2.4. Antihypertensive
11.13. U.K. Stroke management Market Forecast, By Application
11.13.1. Ischemic Stroke
11.13.2. Haemorrhagic Stroke
11.14. France Stroke management Market Forecast, By Type
11.14.1. Diagnostics
11.14.1.1. Computed Tomography Scan (CT Scan),
11.14.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.14.1.3. Carotid Ultrasound,
11.14.1.4. Cerebral Angiography,
11.14.1.5. Electrocardiography
11.14.2. Therapeutics
11.14.2.1. Tissue Plasminogen Activator,
11.14.2.2. Anticoagulant,
11.14.2.3. Antiplatelet,
11.14.2.4. Antihypertensive
11.15. France Stroke management Market Forecast, By Application
11.15.1. Ischemic Stroke
11.15.2. Haemorrhagic Stroke
11.16. Italy Stroke management Market Forecast, By Type
11.16.1. Diagnostics
11.16.1.1. Computed Tomography Scan (CT Scan),
11.16.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.16.1.3. Carotid Ultrasound,
11.16.1.4. Cerebral Angiography,
11.16.1.5. Electrocardiography
11.16.2. Therapeutics
11.16.2.1. Tissue Plasminogen Activator,
11.16.2.2. Anticoagulant,
11.16.2.3. Antiplatelet,
11.16.2.4. Antihypertensive
11.17. Italy Stroke management Market Forecast, By Application
11.17.1. Ischemic Stroke
11.17.2. Haemorrhagic Stroke
11.18. Spain Stroke management Market Forecast, By Type
11.18.1. Diagnostics
11.18.1.1. Computed Tomography Scan (CT Scan),
11.18.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.18.1.3. Carotid Ultrasound,
11.18.1.4. Cerebral Angiography,
11.18.1.5. Electrocardiography
11.18.2. Therapeutics
11.18.2.1. Tissue Plasminogen Activator,
11.18.2.2. Anticoagulant,
11.18.2.3. Antiplatelet,
11.18.2.4. Antihypertensive
11.19. Spain Stroke management Market Forecast, By Application
11.19.1. Ischemic Stroke
11.19.2. Haemorrhagic Stroke
11.20. Rest of Europe Stroke management Market Forecast, By Type
11.20.1. Diagnostics
11.20.1.1. Computed Tomography Scan (CT Scan),
11.20.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
11.20.1.3. Carotid Ultrasound,
11.20.1.4. Cerebral Angiography,
11.20.1.5. Electrocardiography
11.20.2. Therapeutics
11.20.2.1. Tissue Plasminogen Activator,
11.20.2.2. Anticoagulant,
11.20.2.3. Antiplatelet,
11.20.2.4. Antihypertensive
11.21. Rest of Europe Stroke management Market Forecast, By Application
11.21.1. Ischemic Stroke
11.21.2. Haemorrhagic Stroke
11.22. Europe Stroke management Market Attractiveness Analysis
11.22.1. By Type
11.22.2. By Application
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Stroke management Market Analysis
12.1. Key Findings
12.2. Asia Pacific Stroke management Market Overview
12.3. Asia Pacific Stroke management Market Value Share Analysis, By Type
12.4. Asia Pacific Stroke management Market Forecast, By Type
12.4.1. Diagnostics
12.4.1.1. Computed Tomography Scan (CT Scan),
12.4.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
12.4.1.3. Carotid Ultrasound,
12.4.1.4. Cerebral Angiography,
12.4.1.5. Electrocardiography
12.4.2. Therapeutics
12.4.2.1. Tissue Plasminogen Activator,
12.4.2.2. Anticoagulant,
12.4.2.3. Antiplatelet,
12.4.2.4. Antihypertensive
12.5. Asia Pacific Stroke management Market Value Share Analysis, By Application
12.6. Asia Pacific Stroke management Market Forecast, By Application
12.6.1. Ischemic Stroke
12.6.2. Haemorrhagic Stroke,
12.7. Asia Pacific Stroke management Market Value Share Analysis, by Country
12.8. Asia Pacific Stroke management Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Stroke management Market Analysis, by Country
12.10. China Stroke management Market Forecast, By Type
12.10.1. Diagnostics
12.10.1.1. Computed Tomography Scan (CT Scan),
12.10.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
12.10.1.3. Carotid Ultrasound,
12.10.1.4. Cerebral Angiography,
12.10.1.5. Electrocardiography
12.10.2. Therapeutics
12.10.2.1. Tissue Plasminogen Activator,
12.10.2.2. Anticoagulant,
12.10.2.3. Antiplatelet,
12.10.2.4. Antihypertensive
12.11. China Stroke management Market Forecast, By Application
12.11.1. Ischemic Stroke
12.11.2. Haemorrhagic Stroke
12.12. India Stroke management Market Forecast, By Type
12.12.1. Diagnostics
12.12.1.1. Computed Tomography Scan (CT Scan),
12.12.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
12.12.1.3. Carotid Ultrasound,
12.12.1.4. Cerebral Angiography,
12.12.1.5. Electrocardiography
12.12.2. Therapeutics
12.12.2.1. Tissue Plasminogen Activator,
12.12.2.2. Anticoagulant,
12.12.2.3. Antiplatelet,
12.12.2.4. Antihypertensive
12.13. India Stroke management Market Forecast, By Application
12.13.1. Ischemic Stroke
12.13.2. Haemorrhagic Stroke
12.14. Japan Stroke management Market Forecast, By Type
12.14.1. Diagnostics
12.14.1.1. Computed Tomography Scan (CT Scan),
12.14.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
12.14.1.3. Carotid Ultrasound,
12.14.1.4. Cerebral Angiography,
12.14.1.5. Electrocardiography
12.14.2. Therapeutics
12.14.2.1. Tissue Plasminogen Activator,
12.14.2.2. Anticoagulant,
12.14.2.3. Antiplatelet,
12.14.2.4. Antihypertensive
12.15. Japan Stroke management Market Forecast, By Application
12.15.1. Ischemic Stroke
12.15.2. Haemorrhagic Stroke
12.16. ASEAN Stroke management Market Forecast, By Type
12.16.1. Diagnostics
12.16.1.1. Computed Tomography Scan (CT Scan),
12.16.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
12.16.1.3. Carotid Ultrasound,
12.16.1.4. Cerebral Angiography,
12.16.1.5. Electrocardiography
12.16.2. Therapeutics
12.16.2.1. Tissue Plasminogen Activator,
12.16.2.2. Anticoagulant,
12.16.2.3. Antiplatelet,
12.16.2.4. Antihypertensive
12.17. ASEAN Stroke management Market Forecast, By Application
12.17.1. Ischemic Stroke
12.17.2. Haemorrhagic Stroke
12.18. Rest of Asia Pacific Stroke management Market Forecast, By Type
12.18.1. Diagnostics
12.18.1.1. Computed Tomography Scan (CT Scan),
12.18.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
12.18.1.3. Carotid Ultrasound,
12.18.1.4. Cerebral Angiography,
12.18.1.5. Electrocardiography
12.18.2. Therapeutics
12.18.2.1. Tissue Plasminogen Activator,
12.18.2.2. Anticoagulant,
12.18.2.3. Antiplatelet,
12.18.2.4. Antihypertensive
12.19. Rest of Asia Pacific Stroke management Market Forecast, By Application
12.19.1. Ischemic Stroke
12.19.2. Haemorrhagic Stroke
12.20. Asia Pacific Stroke management Market Attractiveness Analysis
12.20.1. By Type
12.20.2. By Application
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Stroke management Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Stroke management Market Overview
13.3. Middle East & Africa Stroke management Market Value Share Analysis, By Type
13.4. Middle East & Africa Stroke management Market Forecast, By Type
13.4.1. Diagnostics
13.4.1.1. Computed Tomography Scan (CT Scan),
13.4.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
13.4.1.3. Carotid Ultrasound,
13.4.1.4. Cerebral Angiography,
13.4.1.5. Electrocardiography
13.4.2. Therapeutics
13.4.2.1. Tissue Plasminogen Activator,
13.4.2.2. Anticoagulant,
13.4.2.3. Antiplatelet,
13.4.2.4. Antihypertensive
13.5. Middle East & Africa Stroke management Market Value Share Analysis, By Application
13.6. Middle East & Africa Stroke management Market Forecast, By Application
13.6.1. Ischemic Stroke
13.6.2. Haemorrhagic Stroke
13.7. Middle East & Africa Stroke management Market Value Share Analysis, by Country
13.8. Middle East & Africa Stroke management Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Stroke management Market Analysis, by Country
13.10. GCC Stroke management Market Forecast, By Type
13.10.1. Diagnostics
13.10.1.1. Computed Tomography Scan (CT Scan),
13.10.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
13.10.1.3. Carotid Ultrasound,
13.10.1.4. Cerebral Angiography,
13.10.1.5. Electrocardiography
13.10.2. Therapeutics
13.10.2.1. Tissue Plasminogen Activator,
13.10.2.2. Anticoagulant,
13.10.2.3. Antiplatelet,
13.10.2.4. Antihypertensive
13.11. GCC Stroke management Market Forecast, By Application
13.11.1. Ischemic Stroke
13.11.2. Haemorrhagic Stroke
13.12. South Africa Stroke management Market Forecast, By Type
13.12.1. Diagnostics
13.12.1.1. Computed Tomography Scan (CT Scan),
13.12.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
13.12.1.3. Carotid Ultrasound,
13.12.1.4. Cerebral Angiography,
13.12.1.5. Electrocardiography
13.12.2. Therapeutics
13.12.2.1. Tissue Plasminogen Activator,
13.12.2.2. Anticoagulant,
13.12.2.3. Antiplatelet,
13.12.2.4. Antihypertensive
13.13. South Africa Stroke management Market Forecast, By Application
13.13.1. Ischemic Stroke
13.13.2. Haemorrhagic Stroke
13.14. Rest of Middle East & Africa Stroke management Market Forecast, By Type
13.14.1. Diagnostics
13.14.1.1. Computed Tomography Scan (CT Scan),
13.14.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
13.14.1.3. Carotid Ultrasound,
13.14.1.4. Cerebral Angiography,
13.14.1.5. Electrocardiography
13.14.2. Therapeutics
13.14.2.1. Tissue Plasminogen Activator,
13.14.2.2. Anticoagulant,
13.14.2.3. Antiplatelet,
13.14.2.4. Antihypertensive
13.15. Rest of Middle East & Africa Stroke management Market Forecast, By Application
13.15.1. Ischemic Stroke
13.15.2. Haemorrhagic Stroke
13.16. Middle East & Africa Stroke management Market Attractiveness Analysis
13.16.1. By Type
13.16.2. By Application
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Stroke management Market Analysis
14.1. Key Findings
14.2. South America Stroke management Market Overview
14.3. South America Stroke management Market Value Share Analysis, By Type
14.4. South America Stroke management Market Forecast, By Type
14.4.1. Diagnostics
14.4.1.1. Computed Tomography Scan (CT Scan),
14.4.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
14.4.1.3. Carotid Ultrasound,
14.4.1.4. Cerebral Angiography,
14.4.1.5. Electrocardiography
14.4.2. Therapeutics
14.4.2.1. Tissue Plasminogen Activator,
14.4.2.2. Anticoagulant,
14.4.2.3. Antiplatelet,
14.4.2.4. Antihypertensive
14.5. South America Stroke management Market Value Share Analysis, By Application
14.6. South America Stroke management Market Forecast, By Application
14.6.1. Ischemic Stroke
14.6.2. Haemorrhagic Stroke
14.7. South America Stroke management Market Value Share Analysis, by Country
14.8. South America Stroke management Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Stroke management Market Forecast, By Type
14.9.1. Diagnostics
14.9.1.1. Computed Tomography Scan (CT Scan),
14.9.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
14.9.1.3. Carotid Ultrasound,
14.9.1.4. Cerebral Angiography,
14.9.1.5. Electrocardiography
14.9.2. Therapeutics
14.9.2.1. Tissue Plasminogen Activator,
14.9.2.2. Anticoagulant,
14.9.2.3. Antiplatelet,
14.9.2.4. Antihypertensive
14.10. Brazil Stroke management Market Forecast, By Application
14.10.1. Ischemic Stroke
14.10.2. Haemorrhagic Stroke
14.11. Mexico Stroke management Market Forecast, By Type
14.11.1. Diagnostics
14.11.1.1. Computed Tomography Scan (CT Scan),
14.11.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
14.11.1.3. Carotid Ultrasound,
14.11.1.4. Cerebral Angiography,
14.11.1.5. Electrocardiography
14.11.2. Therapeutics
14.11.2.1. Tissue Plasminogen Activator,
14.11.2.2. Anticoagulant,
14.11.2.3. Antiplatelet,
14.11.2.4. Antihypertensive
14.12. Mexico Stroke management Market Forecast, By Application
14.12.1. Ischemic Stroke
14.12.2. Haemorrhagic Stroke
14.13. Rest of South America Stroke management Market Forecast, By Type
14.13.1. Diagnostics
14.13.1.1. Computed Tomography Scan (CT Scan),
14.13.1.2. Echocardiography Magnetic Resonance Imaging (MRI)
14.13.1.3. Carotid Ultrasound,
14.13.1.4. Cerebral Angiography,
14.13.1.5. Electrocardiography
14.13.2. Therapeutics
14.13.2.1. Tissue Plasminogen Activator,
14.13.2.2. Anticoagulant,
14.13.2.3. Antiplatelet,
14.13.2.4. Antihypertensive
14.14. Rest of South America Stroke management Market Forecast, By Application
14.14.1. Ischemic Stroke
14.14.2. Haemorrhagic Stroke
14.15. South America Stroke management Market Attractiveness Analysis
14.15.1. By Type
14.15.2. By Application
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Type Launches and Type Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. Abbott Laboratories
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Type Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint

15.3.2. Covidien PLC
15.3.3. GE Healthcare
15.3.4. Hitachi, Ltd
15.3.5. Johnson and Johnson
15.3.6. Penumbra, Inc.
15.3.7. Philips Healthcare
15.3.8. Siemens Healthcare
15.3.9. Stryker Corporation (Concentric Medical, Inc.)
15.3.10. B. Braun Melsungen Ag
15.3.11. Boston Scientific Corporation
15.3.12. Cardinal Health, Inc.
15.3.13. Glaxosmithkline Plc
15.3.14. Medtronic Plc.
15.3.15. Merck & Co., Inc.
15.3.16. Bristol-Myers Squibb Company
15.3.17. Koninklijke Philips N.V.
15.3.18. ZOLL Medical Corporation
15.3.19. Mizuho Medical Co., Ltd.
15.3.20. Integer Holdings Corporation
15.3.21. GENERAL ELECTRIC COMPANY
15.3.22. Kaneka Pharma America LLC
15.3.23. Silk Road Medical
15.3.24. Teleflex Incorporated

16. Primary Key Insights
  • INQUIRE BEFORE BUYING